# Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

> **NCT00128531** · PHASE3 · COMPLETED · sponsor: **GP-Pharm** · enrollment: 120 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** leuprolide acetate

## Key facts

- **NCT ID:** NCT00128531
- **Lead sponsor:** GP-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 120 (—)
- **Last updated:** 2007-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128531, "Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00128531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*